SCHEMBL614717

SCHEMBL614717

Nc1cc(F)c(C(=O)O)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
KDM4E B2RXH2 5/20 0.39
TDP1 Q9NUW8 4/20 0.39
KEAP1 Q14145 2/20 0.39
ALDH1A1 P00352 4/20 0.35
MAPT P10636 3/20 0.35
THRB P10828 2/20 0.35
RECQL P46063 2/20 0.35
CYP3A4 P08684 2/20 0.35
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
HSD17B10 Q99714 2/20 0.35
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.35
PKM P14618 1/20 0.35
APEX1 P27695 1/20 0.35
BLM P54132 1/20 0.35
MCL1 Q07820 1/20 0.35
TNF P01375 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL31538137 0.85 KDM4E (0.46) MEN1KMT2AKDM4ETDP1KEAP1
SCHEMBL9769361 0.85 THRB (0.41) MEN1KMT2AKDM4ETDP1KEAP1
Ammonia Solution, Strong SCHEMBL31538196 0.85 KDM4E (0.46) MEN1KMT2AKDM4ETDP1KEAP1
SCHEMBL9769198 0.82 GLA (0.38) MEN1KMT2AKDM4ETDP1KEAP1
SCHEMBL4262805 0.80 DGAT1 (0.38) MEN1KMT2AKDM4ETDP1KEAP1
SCHEMBL28888036 0.79 AKR1C2 (0.45) KDM4ETDP1KEAP1ALDH1A1MAPT
SCHEMBL288979 0.79 CES2 (0.46) MEN1KMT2AKDM4ETDP1KEAP1
Hydrochloric Acid SCHEMBL17629791 0.78 DGAT1 (0.36) MEN1KMT2AKDM4ETDP1MAPT
SCHEMBL6192201 0.78 KMT2A (0.39) MEN1KMT2AKDM4ETDP1ALDH1A1
SCHEMBL29154306 0.77 CES2 (0.44) MEN1KMT2AKDM4ETDP1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404274-B2 Macrocycles as factor xia inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-02 US disclosed
EP-4541422-A2 QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS Gilead Sciences, Inc. (US) 2025-04-23 EP disclosed
CN-119462635-A Quinoline derivatives as alpha 4 beta 7 integrin inhibitors 吉利德科学公司 2025-02-18 CN disclosed
US-20250032473-A1 QUINOLINE DERIVATIVES GILEAD SCIENCES, INC. 2025-01-30 US disclosed
EP-3873884-B1 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDIN-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES GILEAD SCIENCES INC (US) 2024-12-04 EP disclosed
CN-112969687-B Quinoline derivatives as a4 b 7 integrin inhibitors 吉利德科学公司 2024-08-23 CN disclosed
US-12053462-B2 Quinoline derivatives GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
CN-116987066-A Pyrimidine compound and preparation method and application thereof 四川大学 2023-11-03 CN disclosed
CN-107973809-B Macrocyclic compounds as factor XIA inhibitors 百时美施贵宝公司 2023-06-30 CN disclosed
US-20230058729-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2023-02-23 US disclosed
EP-0647217-B1 4-ACYLAMINOBENZAMIDES AND THEIR USE AS FUNGICIDES ZENECA LTD (GB) 1997-10-29 EP disclosed
WO-1997030035-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ZENECA LIMITED (GB) 1997-08-21 WO disclosed
WO-1997024116-A2 METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY VISION PHARMACEUTICALS L.P. (US) 1997-07-10 WO disclosed
WO-1997019062-A1 SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY ALLERGAN (US) 1997-05-29 WO disclosed
WO-1997019052-A1 ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY ALLERGAN (US) 1997-05-29 WO disclosed
EP-0647217-A1 4-ACYLAMINOBENZAMIDES AND THEIR USE AS FUNGICIDES. ZENECA LTD (GB) 1995-04-12 EP disclosed
CN-1090269-A Mycocide ZENECA LTD (GB) 1994-08-03 CN disclosed
WO-1994000422-A2 4-ACYLAMINOBENZAMIDES AND THEIR USE AS FUNGICIDES ZENECA LIMITED (GB) 1994-01-06 WO disclosed
WO-1993014063-A1 FUNGICIDES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-07-22 WO disclosed
US-5068436-A Hydrogenation of halonitrobenzenes without dehalogenation E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12053462-B2 Quinoline derivatives CFTR, NQO1, IRF3 MEN1 2786/4885KMT2A 2755/4885KDM4E 2522/4885
US-12404274-B2 Macrocycles as factor xia inhibitors TFPI, TFPI2, F11 MEN1 376/4885KMT2A 1111/4885KDM4E 796/4885
US-20230058729-A1 MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F11 MEN1 376/4885KMT2A 1111/4885KDM4E 796/4885
US-20250032473-A1 QUINOLINE DERIVATIVES CFTR, NQO1, IRF3 MEN1 2786/4885KMT2A 2755/4885KDM4E 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.